Free tool
FAERS Monitor: Arcalyst
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125249 or its brand name (Arcalyst, Rilonacept). Reports on generic versions are filed under their own applications.
Reports
1,157
Serious
284
25% of reports
Hospitalization
134
Death reported
26
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- injection site erythema134
- chest pain120
- product dose omission issue103
- pericarditis90
- fatigue89
- injection site pain88
- off label use85
- drug ineffective76
- pain76
- injection site pruritus68
- injection site rash67
- dyspnoea63
- injection site reaction59
- arthralgia57
- chest discomfort50
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 5 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 4 |
| 2013 | 10 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 14 |
| 2017 | 9 |
| 2018 | 21 |
| 2019 | 10 |
| 2020 | 7 |
| 2021 | 15 |
| 2022 | 170 |
| 2023 | 73 |
| 2024 | 190 |
| 2025 | 399 |
| 2026 | 219 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,002 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pericarditisSignal | 90 | 97.9 | 80.2 | 8,497 |
| injection site rashSignal | 67 | 39.8 | 31.5 | 2,493 |
| injection site erythemaSignal | 134 | 19.7 | 16.8 | 2,366 |
| injection site pruritusSignal | 68 | 18.5 | 14.7 | 1,109 |
| injection site reactionSignal | 59 | 15.6 | 12.2 | 794 |
| chest painSignal | 120 | 11.8 | 9.9 | 1,183 |
| chest discomfortSignal | 50 | 8.9 | 6.8 | 343 |
| product dose omission issueSignal | 103 | 6.4 | 5.3 | 467 |
| injection site painSignal | 88 | 5.2 | 4.3 | 300 |
| arthralgiaSignal | 57 | 2.5 | 1.9 | 50 |
| painSignal | 76 | 2.2 | 1.8 | 53 |
| fatigueSignal | 89 | 2.1 | 1.7 | 51 |
| dyspnoeaSignal | 63 | 2.0 | 1.6 | 32 |
| off label use | 85 | 1.8 | 1.4 | 29 |
| drug ineffective | 76 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.